Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Why should autologous transplant remain the SOC in myeloma?

Amrita Krishnan • 29 Sep 2022
SOHO 2022
Multiple Myeloma
DETERMINATION

Amrita Krishnan, MD, City of Hope, Duarte, CA, briefly explains the benefits of autologous transplantation in multiple myeloma, and why this should remain the standard of care (SOC) in the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Amrita Krishnan

0:49
Management of patients with penta-class refractory myeloma
Amrita Krishnan • 11 Dec 2023
1:01
Considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma
Amrita Krishnan • 11 Dec 2023
0:50
Dose modifications of talquetamab to manage AEs in patients with multiple myeloma
Amrita Krishnan • 11 Dec 2023
1:15
How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myeloma
Amrita Krishnan • 29 Sep 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals